Navigation Links
Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
Date:5/1/2012

forma basis in the first quarter of 2012, compared with same period last year.  Net sales declines in Women's Health were driven by year-over-year declines in procedural volumes.
Procedural volumes stabilized sequentially in Women's Health  as physician and patient education activities continue to improve understanding of the safety profiles for the company's effective surgical mesh therapy offerings.HEALTH TRONICSServices sales of $52 million for the first quarter 2012 represented an increase of 3 percent over last year, as a result of improved access to equipment for patients and physicians.  The company expects improved top-line growth from the Services segment in 2012 and beyond from the recent addition of an electronic medical records offering that is focused on practices specializing in urology, an expanding set of partnerships in our Endocare® cryoablation therapy as well as our pilot programs involving the sales of this device through the AMS channel. 

2012 Financial GuidanceEndo now expects for full year 2012:

  • Reported (GAAP) diluted earnings per share between $1.75 and $1.95
  • Endo reiterated full year 2012 financial guidance as follows:

  • Total revenue between $3.15 billion and $3.30 billion
  • Total Branded Pharmaceuticals segment revenue between $1.740 billion and $1.800 billion
  • Total Generics segment revenue between $635 million and $675 million
  • Total Devices segment revenue between $530 million and $570 million
  • Total Services segment revenue between $240 million and $260 million
  • Adjusted diluted earnings per share between $5.00 and $5.20
  • Cash flow from operations between $750 million and $850 million
  • Capital expenditures to be approximately $100 million
  • Endo's 2012 guidance is based on certain current assumptions including:

  • Adjusted gross margin between 68 percent and 69 percent
  • Adjusted effect
    '/>"/>

  • SOURCE Endo
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. Hospira Reports First-Quarter 2012 Results
    2. Luminex Corporation Reports First Quarter 2012 Results
    3. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
    4. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
    5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
    6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
    7. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
    8. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    9. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    10. Cepheid Reports 2012 First Quarter Results
    11. Sotera Wireless Reports FDA Clearance of ViSi Mobile™ System
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... condition to the announced tender offer for all of the outstanding ... result of the waiver, the transaction is no longer conditional on ... January 24, 2014 following the currently scheduled expiration time, subject to ...
    (Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
    (Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
    Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
    ... October 12, 2011 Aircraft Medical ("Aircraft"), ... has signed an exclusive agreement with Covidien (NYSE: ... products with 2010 revenue of $10.4 billion, and 41,000 ... agreement, Covidien will market and distribute Aircraft,s proprietary McGRATH ...
    ... October 12, 2011 OctreoPharm Sciences ... today that the European Medicines Agency has granted ... for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours. ... to ten year market exclusivity in Europe following ...
    Cached Medicine Technology:Aircraft Medical Signs Multinational Distribution Agreement with Covidien for McGRATH® MAC Video Laryngoscope 2OctreoPharm Sciences Receives Orphan Drug Designation for SOMscan® for the Diagnosis of Neuroendocrine Tumours 2
    (Date:4/24/2014)... A Finnish team of researchers was the first in ... which is a tumour of the jaw. , Ameloblastoma ... recur after treatment. Ameloblastoma is most often found in ... by surgery, often resulting in tissue deficiencies in the ... suitable drug therapy could reduce the need for surgery ...
    (Date:4/24/2014)... the University of York reveals that a process that ... nervous system may also play a pivotal role in ... led by Dr Will Brackenbury, a Medical Research Council ... studied how voltage-gated sodium channels assist in the metastasis ... membranes of excitable cells, such as neurons, where they ...
    (Date:4/23/2014)... SPOKANE, Wash.Researchers at Washington State University Spokane have ... are about to nod off behind the wheel. ... steering wheel movementswhich are more variable in drowsy ... to currently available video-based driver drowsiness detection systems. ... detect when a car is drifting out of ...
    (Date:4/23/2014)... Ind. - Purdue University researchers have developed a way ... cell by using tiny gold particles with tails of ... of agricultural and biological engineering, used gold nanoparticles to ... as BRCA1 messenger RNA splice variants, which can indicate ... of these mRNA splice variants in a cell can ...
    (Date:4/23/2014)... program could help doctors predict which patients might suffer ... , The program, which assesses brain scans using pattern ... and passport control, has been developed by researchers at ... by the Wellcome Trust, which used the software are ... , Stroke affects over 15 million people each year ...
    Breaking Medicine News(10 mins):Health News:Breast cancer replicates brain development process 2Health News:WSU innovation improves drowsy driver detection 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3
    ... Highlights Key Issues and Offers Suggestions on ... Improvements for Hospital Administrators, NEW YORK, March ... delivery of a baby is a significant decision. But,there are ... departments,around the country that must function properly in order to ...
    ... on more than 17,000 people with coronary artery disease ... Treatment with an ACE inhibitor drug was as effective ... high-risk group of patients as a newer and more ... has found. , The study of more than 17,000 ...
    ... ANN ARBOR, Mich. An international blood pressure study ... significant that the study has been stopped early ... way high blood pressure is treated worldwide. , ... people who had high blood pressure and other cardiovascular ...
    ... 2008 New data from a clinical trial ... patients living with type 2 diabetes, ACTOS® (pioglitazone ... arteries compared to glimepiride, and prevented progression compared ... PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic ...
    ... new,public health campaign created by an alliance of ... in Washington, DC. The program,called EX(R), will change ... quitting, and guide them to valuable free resources ... Fairness Doctrine was applied to,tobacco in 1968-1970 have ...
    ... Industry Leaders,Association (RILA) today filed a friend-of-the-court (amicus) ... Court of Appeals for,the Ninth Circuit challenging the ... The case, Golden Gate Restaurant Association v. City ... Health Care Security Ordinance,which mandates health insurance coverage ...
    Cached Medicine News:Health News:OB Challenges Create Hospital Opportunities in 2008 2Health News:OB Challenges Create Hospital Opportunities in 2008 3Health News:OB Challenges Create Hospital Opportunities in 2008 4Health News:ACE Inhibitor as Effective as More Expensive Blood Pressure Drug 2Health News:2-drug blood pressure therapy lowers cardiovascular risk 2Health News:2-drug blood pressure therapy lowers cardiovascular risk 3Health News:New data showed Actos prevented progression of atherosclerotic plaque volume in patients 2Health News:New National Public Health Program Shows Smokers How to Become an EX 2Health News:New National Public Health Program Shows Smokers How to Become an EX 3Health News:New National Public Health Program Shows Smokers How to Become an EX 4Health News:New National Public Health Program Shows Smokers How to Become an EX 5Health News:Retail Industry Leaders Association Files Amicus in California Health Care Litigation 2
    ... Triage BNP Test is the first ... measuring B-type natriuretic peptide (BNP) ,Cardiac ... in response to ventricular volume expansion ... of ventricular systolic and diastolic dysfunction. ...
    ... Building on over 20 years of ... platforms for the Life Sciences, the ... flexibility and possibilities for expansion according ... new easy-to-use software, Freedom EVOware, each ...
    ... (OSS) from Biomet Inc. offers the ... specifically for orthopaedic surgeons and oncologists ... their patients: significant bone loss, ligamentous ... arthroplasties, and multiple hip revision arthroplasties. ...
    The generously sized STERILE VIEW Monk Hood from DePuy provides splash protection in the chin and neck areas from body fluids and liquids. Shoulder cut outs and ties ensure a comfortable fit. This pr...
    Medicine Products: